Refine
Has Fulltext
- yes (51)
Is part of the Bibliography
- yes (51)
Year of publication
Document Type
- Journal article (51)
Language
- English (51)
Keywords
- heart failure (12)
- mortality (5)
- echocardiography (4)
- myocardial infarction (4)
- coronary artery disease (3)
- ejection fraction (3)
- guideline adherence (3)
- hypertension (3)
- prognosis (3)
- GFAP (2)
- acute heart failure (2)
- amyloidosis (2)
- cardiac magnetic resonance imaging (2)
- cardiac surgery (2)
- cardiomyopathy (2)
- chronic kidney disease (2)
- cognitive impairment (2)
- coronary heart disease (2)
- deformation (2)
- diagnosis (2)
- guidelines (2)
- ischemic stroke (2)
- left ventricular ejection fraction (2)
- management (2)
- myocardial work (2)
- neurofilament light chain (2)
- prevalence (2)
- validation (2)
- 2-dimensional speckle tracking (1)
- ACC/AHA classification (1)
- AKI (1)
- Akutes Nierenversagen (1)
- Alzheimer's disease (1)
- Alzheimer’s dementia (1)
- BDNF (1)
- Brain atrophy (1)
- COMT (1)
- COPD diagnosis (1)
- COVID-19 (1)
- Cardiac dysfunction| Brain natriuretic peptide (1)
- CardioMEMS™ HF-System (1)
- Cardiovascular magnetic-resonance (1)
- Cardiovascular risk factors (1)
- Cardiovascular risk prediction (1)
- Carotid intima-media thickness (CIMT) (1)
- Carotid segment (1)
- Carotid ultrasound (1)
- Chronic heart failure (1)
- Cognitive decline (1)
- Coronary artery disease (1)
- Diastocic Dysfunction (1)
- ESC (1)
- EUROASPIRE survey (1)
- Enzyme replacement therapy (1)
- Eplerenone (1)
- Framingham (1)
- GDNF (1)
- GOLD (1)
- Glial fibrillary acidic protein (1)
- Guidelines (1)
- Heart failure (1)
- HiGHmed (1)
- Hyperkalemia (1)
- Hypertrophic cardiomyopathy (1)
- ICD-coding of CKD (1)
- KDIGO (1)
- LV dilatation (1)
- MRI (1)
- Management (1)
- Manifestation (1)
- Medizin (1)
- Memory dysfunction (1)
- Morbidity (1)
- Mortality (1)
- Myocardial fibrosis (1)
- Myocardial-Infarction (1)
- NT‐proBNP (1)
- NfL (1)
- Outcomes (1)
- Predictors (1)
- Preserved Ejection Fraction (1)
- ST-elevation myocardial infarction (1)
- STEMI (1)
- Septal bulge (1)
- Stroke (1)
- Task force (1)
- Troponin (1)
- Ventricular-arrhythmias (1)
- accuracy (1)
- acute decompensated heart failure (1)
- acute kidney injury (1)
- adaptive immune response (1)
- age (1)
- age-related hearing loss (1)
- amyloid cardiomyopathy (1)
- anaemia (1)
- anti-myocardial (1)
- anxiety (1)
- aortic valve stenosis (1)
- arterial stiffening (1)
- atherosclerosis (1)
- atrial fibrillation (1)
- autoantibody (1)
- awareness (1)
- biomarker (1)
- biomarkers (1)
- blood coagulation factor XIII (1)
- blood lipids (1)
- blood pressure (1)
- blood pressure monitoring (1)
- blood-glucose (1)
- blood–brain barrier (1)
- blood–labyrinth barrier (1)
- bull’s eye plot (1)
- calcification (1)
- calcium imaging (1)
- cardiac arrest (1)
- cardiac training group (1)
- cardiac transplantation (1)
- cardiopulmonary bypass (1)
- cardiovascular care (1)
- cardiovascular diseases (1)
- cardiovascular magnetic resonance (1)
- cardiovascular risk factors (1)
- carotid artery disease (1)
- chronic heart failure (CHF) (1)
- chronic thromboembolic pulmonary hypertension (1)
- clinical data warehouse (1)
- clinical manifestations (1)
- clinical routine data (1)
- clinical study (1)
- clinical systems (1)
- coaptation line (1)
- comorbidity (1)
- comparability (1)
- congestion (1)
- data warehouse (1)
- death rates (1)
- dementia (1)
- depression (1)
- diagnostic medicine (1)
- digital Health (1)
- digital phenotyping (1)
- disease (1)
- disease score (1)
- disease severity (1)
- dynamic (1)
- ecological momentary assessment (1)
- electronic data capture (1)
- electronic health records (1)
- euroaspire (1)
- evidence-based practice (1)
- fabry disease (1)
- feasibility (1)
- fibrosis (1)
- follow-up (1)
- functional regurgitation (1)
- glial damage (1)
- glial fibrillary acidic protein (1)
- glucose control (1)
- glycaemic control (1)
- guideline implementation (1)
- guideline-directed medical therapy (1)
- healing and remodelling processes (1)
- health care research (1)
- health economics (1)
- health policy (1)
- health questionnaire (1)
- health risk assessment (1)
- heart (1)
- heart disease (1)
- heart failure training group (1)
- heme oxygenase-1 (1)
- home telemonitoring (1)
- hospitalization (1)
- identification (1)
- impact (1)
- incremental cost-effectiveness ratio (ICER) (1)
- infarction size (1)
- inferior vena cava (1)
- inflammation (1)
- information extraction (1)
- internal medicine (1)
- ischemic (1)
- leaflet (1)
- left ventricular geometric abnormality (1)
- left ventricular geometry (1)
- left ventricular hypertrophy (1)
- left ventricular mass (1)
- left ventricular performance (1)
- left ventricular remodeling (1)
- longitudinal studies (1)
- lower limit of normal (1)
- m exercise training (1)
- mHealth (1)
- medical data integration center (1)
- medical informatics initiative (1)
- medication extraction (1)
- mellitus (1)
- metaanalysis (1)
- mineralocorticoid antagonist (1)
- mitral valve (1)
- mobile crowdsensing (1)
- mobile health (1)
- morbidity (1)
- myocardial work efficiency (1)
- myocardial fibrosis (1)
- natriuretic peptide (1)
- neuroinflammation (1)
- neurotrophins (1)
- normal values (1)
- observational study (1)
- oncology (1)
- openEHR (1)
- outcomes (1)
- patients’ awareness (1)
- pharmacotherapy (1)
- phosphorylated tau protein (1)
- physicians’ awareness (1)
- point-of-care echocardiography (1)
- population (1)
- population-based study (1)
- postoperativ (1)
- preserved ejection fraction (1)
- primary prevention (1)
- pulmonary artery pressure (1)
- quality of life (1)
- randomized controlled trial (1)
- real-world (1)
- recovery (1)
- reference data (1)
- regression analysis (1)
- remote monitoring (1)
- renal function (1)
- risk factor control (1)
- risk factors (1)
- risk prediction scores (1)
- sacubitril-valsartan (1)
- scale (1)
- secondary data usage (1)
- secondary prevention (1)
- semantic interoperability (1)
- sex differences (1)
- sodium-glucose co-transporter-2 inhibitors (1)
- speckle tracking imaging (1)
- speech recognition (1)
- spiral ganglion neuron (1)
- standardization (1)
- stem cell transplantation (1)
- stroke unit (1)
- systolic dysfunction (1)
- task force (1)
- telemedicine (1)
- tenting (1)
- therapeutic approach (1)
- therapy (1)
- three-dimensional echocardiography (1)
- treatment (1)
- tricuspid pressure gradient (1)
- troponin (1)
- troponin T (1)
- type 2 diabetes (1)
- ultrasound (1)
- usability (1)
- user-centered design (1)
- validity (1)
Institute
- Medizinische Klinik und Poliklinik I (45)
- Deutsches Zentrum für Herzinsuffizienz (DZHI) (25)
- Institut für Klinische Epidemiologie und Biometrie (16)
- Institut für Informatik (6)
- Klinik und Poliklinik für Thorax-, Herz- u. Thorakale Gefäßchirurgie (6)
- Neurologische Klinik und Poliklinik (5)
- Institut für diagnostische und interventionelle Radiologie (Institut für Röntgendiagnostik) (4)
- Klinik und Poliklinik für Psychiatrie, Psychosomatik und Psychotherapie (3)
- Medizinische Klinik und Poliklinik II (3)
- Institut für Virologie und Immunbiologie (2)
Sonstige beteiligte Institutionen
Usability of a mHealth solution using speech recognition for point-of-care diagnostic management
(2023)
The administrative burden for physicians in the hospital can affect the quality of patient care. The Service Center Medical Informatics (SMI) of the University Hospital Würzburg developed and implemented the smartphone-based mobile application (MA) ukw.mobile1 that uses speech recognition for the point-of-care ordering of radiological examinations. The aim of this study was to examine the usability of the MA workflow for the point-of-care ordering of radiological examinations. All physicians at the Department of Trauma and Plastic Surgery at the University Hospital Würzburg, Germany, were asked to participate in a survey including the short version of the User Experience Questionnaire (UEQ-S) and the Unified Theory of Acceptance and Use of Technology (UTAUT). For the analysis of the different domains of user experience (overall attractiveness, pragmatic quality and hedonic quality), we used a two-sided dependent sample t-test. For the determinants of the acceptance model, we employed regression analysis. Twenty-one of 30 physicians (mean age 34 ± 8 years, 62% male) completed the questionnaire. Compared to the conventional desktop application (DA) workflow, the new MA workflow showed superior overall attractiveness (mean difference 2.15 ± 1.33), pragmatic quality (mean difference 1.90 ± 1.16), and hedonic quality (mean difference 2.41 ± 1.62; all p < .001). The user acceptance measured by the UTAUT (mean 4.49 ± 0.41; min. 1, max. 5) was also high. Performance expectancy (beta = 0.57, p = .02) and effort expectancy (beta = 0.36, p = .04) were identified as predictors of acceptance, the full predictive model explained 65.4% of its variance. Point-of-care mHealth solutions using innovative technology such as speech-recognition seem to address the users’ needs and to offer higher usability in comparison to conventional technology. Implementation of user-centered mHealth innovations might therefore help to facilitate physicians’ daily work.
Background
The importance of chronic kidney disease (CKD) and anaemia has not been comprehensively studied in asymptomatic patients at risk for heart failure (HF) versus those with symptomatic HF. We analysed the prevalence, characteristics and prognostic impact of both conditions across American College of Cardiology/American Heart Association (ACC/AHA) precursor and HF stages A–D.
Methods and results
2496 participants from three non-pharmacological German Competence Network HF studies were categorized by ACC/AHA stage; stage C patients were subdivided into C1 and C2 (corresponding to NYHA classes I/II and III, respectively). Overall, patient distribution was 8.1%/35.3%/32.9% and 23.7% in ACC/AHA stages A/B/C1 and C2/D, respectively. These subgroups were stratified by the absence ( – ) or presence ( +) of CKD (estimated glomerular filtration rate [eGFR] < 60 mL/min/1.73m2) and anaemia (haemoglobin in women/men < 12/ < 13 g/dL). The primary outcome was all-cause mortality at 5-year follow-up. Prevalence increased across stages A/B/C1 and C2/D (CKD: 22.3%/23.6%/31.6%/54.7%; anaemia: 3.0%/7.9%/21.7%/33.2%, respectively), with concordant decreases in median eGFR and haemoglobin (all p < 0.001). Across all stages, hazard ratios [95% confidence intervals] for all-cause mortality were 2.1 [1.8–2.6] for CKD + , 1.7 [1.4–2.0] for anaemia, and 3.6 [2.9–4.6] for CKD + /anaemia + (all p < 0.001). Population attributable fractions (PAFs) for 5-year mortality related to CKD and/or anaemia were similar across stages A/B, C1 and C2/D (up to 33.4%, 30.8% and 34.7%, respectively).
Conclusions
Prevalence and severity of CKD and anaemia increased across ACC/AHA stages. Both conditions were individually and additively associated with increased 5-year mortality risk, with similar PAFs in asymptomatic patients and those with symptomatic HF.
We assume that a specific health constraint, e.g., a certain aspect of bodily function or quality of life that is measured by a variable X, is absent (or irrelevant) in a healthy reference population (Ref0), and it is materially present and precisely measured in a diseased reference population (Ref1). We further assume that some amount of this constraint of interest is suspected to be present in a population under study (SP). In order to quantify this issue, we propose the introduction of an intuitive measure, the population comparison index (PCI), that relates the mean value of X in population SP to the mean values of X in populations Ref0 and Ref1. This measure is defined as PCI[X] = (mean[X|SP] − mean[X|Ref0])/(mean[X|Ref1] − mean[X|Ref0]) × 100[%], where mean[X|.] is the average value of X in the respective group of individuals. For interpretation, PCI[X] ≈ 0 indicates that the values of X in the population SP are similar to those in population Ref0, and hence, the impairment measured by X is not materially present in the individuals in population SP. On the other hand, PCI[X] ≈ 100 means that the individuals in SP exhibit values of X comparable to those occurring in Ref1, i.e., the constraint of interest is equally present in populations SP and Ref1. A value of 0 < PCI[X] < 100 indicates that a certain percentage of the constraint is present in SP, and it is more than in Ref0 but less than in Ref1. A value of PCI[X] > 100 means that population SP is even more affected by the constraint than population Ref1.
Acute and chronic cardiac disorders predispose to alterations in cognitive performance, ranging from mild cognitive impairment to overt dementia. Although this association is well-established, the factors inducing and accelerating cognitive decline beyond ageing and the intricate causal pathways and multilateral interdependencies involved remain poorly understood. Dysregulated and persistent inflammatory processes have been implicated as potentially causal mediators of the adverse consequences on brain function in patients with cardiac disease. Recent advances in positron emission tomography disclosed an enhanced level of neuroinflammation of cortical and subcortical brain regions as an important correlate of altered cognition in these patients. In preclinical and clinical investigations, the thereby involved domains and cell types of the brain are gradually better characterized. Microglia, resident myeloid cells of the central nervous system, appear to be of particular importance, as they are extremely sensitive to even subtle pathological alterations affecting their complex interplay with neighboring astrocytes, oligodendrocytes, infiltrating myeloid cells, and lymphocytes. Here, we review the current evidence linking cognitive impairment and chronic neuroinflammation in patients with various selected cardiac disorders including the aspect of chronic neuroinflammation as a potentially druggable target.
Background
Guideline-directed medical therapy (GDMT) is the cornerstone in the treatment of patients with heart failure and reduced ejection fraction (HFrEF) and novel substances such as sacubitril/valsartan (S/V) and sodium-glucose co-transporter-2 inhibitors (SGLT2i) have demonstrated marked clinical benefits. We investigated their implementation into real-world HF care in Germany before, during, and after the COVID-19 pandemic period.
Methods
The IQVIA LRx data set is based on ∼80% of 73 million people covered by the German statutory health insurance. Prescriptions of S/V were used as a proxy for HFrEF. Time trends were analysed between Q1/2016 and Q2/2023 for prescriptions for S/V alone and in combination therapy with SGLT2i.
Findings
The number of patients treated with S/V increased from 5260 in Q1/2016 to 351,262 in Q2/2023. The share of patients with combination therapy grew from 0.6% (29 of 5260) to 14.2% (31,128 of 219,762) in Q2/2021, and then showed a steep surge up to 54.8% (192,429 of 351,262) in Q2/2023, coinciding with the release of the European Society of Cardiology (ESC) guidelines for HF in Q3/2021. Women and patients aged >80 years were treated less often with combined therapy than men and younger patients. With the start of the COVID-19 pandemic, the number of patients with new S/V prescriptions dropped by 17.5% within one quarter, i.e., from 26,855 in Q1/2020 to 22,145 in Q2/2020, and returned to pre-pandemic levels only in Q1/2021.
Interpretation
The COVID-19 pandemic was associated with a 12-month deceleration of S/V uptake in Germany. Following the release of the ESC HF guidelines, the combined prescription of S/V and SGLT2i was readily adopted. Further efforts are needed to fully implement GDMT and strengthen the resilience of healthcare systems during public health crises.
Background
Chronic heart failure (HF) is known to increase the risk of developing Alzheimer’s dementia significantly. Thus, detecting and preventing mild cognitive impairment, which is common in patients with HF, is of great importance. Serum biomarkers are increasingly used in neurological disorders for diagnostics, monitoring, and prognostication of disease course. It remains unclear if neuronal biomarkers may help detect cognitive impairment in this high-risk population. Also, the influence of chronic HF and concomitant renal dysfunction on these biomarkers is not well understood.
Methods
Within the monocentric Cognition.Matters-HF study, we quantified the serum levels of phosphorylated tau protein 181 (pTau) and neurofilament light chain (NfL) of 146 extensively phenotyped chronic heart failure patients (aged 32 to 85 years; 15.1% women) using ultrasensitive bead-based single-molecule immunoassays. The clinical work-up included advanced cognitive testing and cerebral magnetic resonance imaging (MRI).
Results
Serum concentrations of NfL ranged from 5.4 to 215.0 pg/ml (median 26.4 pg/ml) and of pTau from 0.51 to 9.22 pg/ml (median 1.57 pg/ml). We detected mild cognitive impairment (i.e., T-score < 40 in at least one cognitive domain) in 60% of heart failure patients. pTau (p = 0.014), but not NfL, was elevated in this group. Both NfL (ρ = − 0.21; p = 0.013) and pTau (ρ = − 0.25; p = 0.002) related to the cognitive domain visual/verbal memory, as well as white matter hyperintensity volume and cerebral and hippocampal atrophy. In multivariable analysis, both biomarkers were independently influenced by age (T = 4.6 for pTau; T = 5.9 for NfL) and glomerular filtration rate (T = − 2.4 for pTau; T = − 3.4 for NfL). Markers of chronic heart failure, left atrial volume index (T = 4.6) and NT-proBNP (T = 2.8), were further cardiological determinants of pTau and NfL, respectively. In addition, pTau was also strongly affected by serum creatine kinase levels (T = 6.5) and ferritin (T = − 3.1).
Conclusions
pTau and NfL serum levels are strongly influenced by age-dependent renal and cardiac dysfunction. These findings point towards the need for longitudinal examinations and consideration of frequent comorbidities when using neuronal serum biomarkers.
Background
Troponin elevation is common in ischemic stroke (IS) patients. The pathomechanisms involved are incompletely understood and comprise coronary and non-coronary causes, e.g. autonomic dysfunction. We investigated determinants of troponin elevation in acute IS patients including markers of autonomic dysfunction, assessed by heart rate variability (HRV) time domain variables.
Methods
Data were collected within the Stroke Induced Cardiac FAILure (SICFAIL) cohort study. IS patients admitted to the Department of Neurology, Würzburg University Hospital, underwent baseline investigation including cardiac history, physical examination, echocardiography, and blood sampling. Four HRV time domain variables were calculated in patients undergoing electrocardiographic Holter monitoring. Multivariable logistic regression with corresponding odds ratios (OR) and 95% confidence intervals (CI) was used to investigate the determinants of high-sensitive troponin T (hs-TnT) levels ≥14 ng/L.
Results
We report results from 543 IS patients recruited between 01/2014–02/2017. Of those, 203 (37%) had hs-TnT ≥14 ng/L, which was independently associated with older age (OR per year 1.05; 95% CI 1.02–1.08), male sex (OR 2.65; 95% CI 1.54–4.58), decreasing estimated glomerular filtration rate (OR per 10 mL/min/1.73 m2 0.71; 95% CI 0.61–0.84), systolic dysfunction (OR 2.79; 95% CI 1.22–6.37), diastolic dysfunction (OR 2.29; 95% CI 1.29–4.02), atrial fibrillation (OR 2.30; 95% CI 1.25–4.23), and increasing levels of C-reactive protein (OR 1.48 per log unit; 95% CI 1.22–1.79). We did not identify an independent association of troponin elevation with the investigated HRV variables.
Conclusion
Cardiac dysfunction and elevated C-reactive protein, but not a reduced HRV as surrogate of autonomic dysfunction, were associated with increased hs-TnT levels in IS patients independent of established cardiovascular risk factors.
Establishing a cardiac training group for patients with heart failure: the "HIP-in-Würzburg" study
(2022)
Background
Exercise training in heart failure (HF) is recommended but not routinely offered, because of logistic and safety-related reasons. In 2020, the German Society for Prevention&Rehabilitation and the German Society for Cardiology requested establishing dedicated ""HF training groups."" Here, we aimed to implement and evaluate the feasibility and safety of one of the first HF training groups in Germany.
Methods
Twelve patients (three women) with symptomatic HF (NYHA class II/III) and an ejection fraction ≤ 45% participated and were offered weekly, physician-supervised exercise training for 1 year. Patients received a wrist-worn pedometer (M430 Polar) and underwent the following assessments at baseline and after 4, 8 and 12 months: cardiopulmonary exercise test, 6-min walk test, echocardiography (blinded reading), and quality of life assessment (Kansas City Cardiomyopathy Questionnaire, KCCQ).
Results
All patients (median age [quartiles] 64 [49; 64] years) completed the study and participated in 76% of the offered 36 training sessions. The pedometer was worn ≥ 1000 min per day over 86% of the time. No cardiovascular events occurred during training. Across 12 months, NT-proBNP dropped from 986 pg/ml [455; 1937] to 483 pg/ml [247; 2322], and LVEF increased from 36% [29;41] to 41% [32;46]%, (p for trend = 0.01). We observed no changes in exercise capacity except for a subtle increase in peak VO2% predicted, from 66.5 [49; 77] to 67 [52; 78]; p for trend = 0.03. The physical function and social limitation domains of the KCCQ improved from 60 [54; 82] to 71 [58; 95, and from 63 [39; 83] to 78 [64; 92]; p for trend = 0.04 and = 0.01, respectively. Positive trends were further seen for the clinical and overall summary scores.
Conclusion
This pilot study showed that the implementation of a supervised HF-exercise program is feasible, safe, and has the potential to improve both quality of life and surrogate markers of HF severity. This first exercise experiment should facilitate the design of risk-adopted training programs for patients with HF.
Aims
There is an ongoing discussion whether the categorization of patients with heart failure according to left ventricular ejection fraction (LVEF) is scientifically justified and clinically relevant. Major efforts are directed towards the identification of appropriate cut-off values to correctly allocate heart failure-specific pharmacotherapy. Alternatively, an LVEF continuum without definite subgroups is discussed. This study aimed to evaluate the natural distribution of LVEF in patients presenting with acutely decompensated heart failure and to identify potential subgroups of LVEF in male and female patients.
Methods and results
We identified 470 patients (mean age 75 ± 11 years, n = 137 female) hospitalized for acute heart failure in whom LVEF could be quantified by Simpson's method in an in-hospital echocardiogram. Non-parametric modelling revealed a bimodal shape of the LVEF distribution. Parametric modelling identified two clusters suggesting two LVEF peaks with mean (variance) of 61% (9%) and 31% (10%), respectively. Sub-differentiation by sex revealed a sex-specific bimodal clustering of LVEF. The respective threshold differentiating between ‘high’ and ‘low’ LVEF was 45% in men and 52% in women.
Conclusions
In patients presenting with acute heart failure, LVEF clustered in two subgroups and exhibited profound sex-specific distributional differences. These findings might enrich the scientific process to identify distinct subgroups of heart failure patients, which might each benefit from respectively tailored (pharmaco)therapies.
Impact of cardiovascular risk factors on myocardial work-insights from the STAAB cohort study
(2022)
Myocardial work is a new echocardiography-based diagnostic tool, which allows to quantify left ventricular performance based on pressure-strain loops, and has been validated against invasively derived pressure-volume measurements. Myocardial work is described by its components (global constructive work [GCW], global wasted work [GWW]) and indices (global work index [GWI], global work efficiency [GWE]). Applying this innovative concept, we characterized the prevalence and severity of subclinical left ventricular compromise in the general population and estimated its association with cardiovascular (CV) risk factors. Within the Characteristics and Course of Heart Failure STAges A/B and Determinants of Progression (STAAB) cohort study we comprehensively phenotyped a representative sample of the population of Würzburg, Germany, aged 30-79 years. Indices of myocardial work were determined in 1929 individuals (49.3% female, mean age 54 ± 12 years). In multivariable analysis, hypertension was associated with a mild increase in GCW, but a profound increase in GWW, resulting in higher GWI and lower GWE. All other CV risk factors were associated with lower GCW and GWI, but not with GWW. The association of hypertension and obesity with GWI was stronger in women. We conclude that traditional CV risk factors impact selectively and gender-specifically on left ventricular myocardial performance, independent of systolic blood pressure. Quantifying active systolic and diastolic compromise by derivation of myocardial work advances our understanding of pathophysiological processes in health and cardiac disease.